Zinab Doha

Prof. Zinab Doha

Molecular and Medical Genetics, Oregon Health & Science University, Portland, Connecticut, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2023 in Pathophysiology
Verified
Journal Article
Open access
PDF file
ZDZinab Doha
Zinab Doha
RSRosalie C. Sears
Rosalie C. Sears
The transcription factor MYC plays a pivotal role in regulating various cellular processes and has been implicated in tumorigenesis across multiple cancer types. MYC has emerged as a master regulator governing tumor intrinsic and tumor microenvironment interactions, supporting tumor progression and driving drug resistance. This review paper aims to provide an overview and discussion of the intricate mechanisms through which MYC influences tumorigenesis and therapeutic resistance in cancer. We delve into the signaling pathways and molecular networks orchestrated by MYC in the context of tumor intrinsic characteristics, such as proliferation, replication stress and DNA repair. Furthermore, we explore the impact of MYC on the tumor microenvironment, including immune evasion, angiogenesis and cancer-associated fibroblast remodeling. Understanding MYC’s multifaceted role in driving drug resistance and tumor progression is crucial for developing targeted therapies and combination treatments that may effectively combat this devastating disease. Through an analysis of the current literature, this review’s goal is to shed light on the complexities of MYC-driven oncogenesis and its potential as a promising therapeutic target.

13 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZDZinab Doha
Zinab Doha
XWXiaoyan Wang
Xiaoyan Wang
NCNicholas L. Calistri
Nicholas L. Calistri
JEJennifer Eng
Jennifer Eng
CDColin J. Daniel
Colin J. Daniel
RSRosalie C. Sears
Rosalie C. Sears
Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.

18 September 2025 in Cancer Research
Verified
Journal Article
Closed access
CBChloe L. Bowman
Chloe L. Bowman
CDColin J. Daniel
Colin J. Daniel
ECEric J. Carlson
Eric J. Carlson
VSVidhi M Shah
Vidhi M Shah
AFAmy S. Farrell
Amy S. Farrell
ELEllen M. Langer
Ellen M. Langer
The prolyl isomerase PIN1 is overexpressed in cancer and contributes to cancer cell–intrinsic phenotypes, including proliferation and migration. However, PIN1 may also function in stromal cells within the tumor microenvironment. In this study, we showed that PIN1 is a critical regulator of pancreatic stellate cell (PSC) state at baseline and in response to the myofibroblast-activating factor TGFβ. Loss or inhibition of PIN1 altered the epigenetic and transcriptional responses of PSCs to TGFβ, preventing PSC differentiation to a myofibroblast state and altering expression of secreted matrix proteins and signaling molecules. Consistent with inhibition of the TGFβ response, low fibroblast PIN1 expression in mouse and human pancreatic ductal adenocarcinoma correlated with low expression of αSMA, a marker of myofibroblast activation. Decreased PIN1 expression at baseline also altered paracrine hepatocyte growth factor (HGF) signaling from fibroblasts to tumor cells. PSCs with low PIN1 expression displayed reduced expression and secretion of HGF, resulting in an attenuation of c-MET receptor phosphorylation and signaling in nearby cancer cells. In allograft models, host PIN1 was critical for normal growth of a subset of pancreatic cancer cell lines that are responsive to HGF signaling. Through the identification of changes to fibroblast activation state and cross-talk following PIN1 loss or inhibition, these data suggest that systemic targeting of PIN1 will suppress the protumorigenic pancreatic ductal adenocarcinoma microenvironment and may differentially affect heterogeneous patient populations. Significance: PIN1 plays a critical role in the response of pancreatic stellate cells to TGFβ and can be targeted to attenuate myofibroblast activation and protumor cross-talk to suppress pancreatic cancer progression.

10 October 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
AKAiah Khateb
Aiah Khateb
ABAhmed Barefah
Ahmed Barefah
ZDZinab Doha
Zinab Doha
MAMarwah M Albakri
Marwah M Albakri
OROsman Radhwi
Osman Radhwi
Esam AzharEsam Azhar
Esam Azhar
Understanding the landscape of bloodstream infections (BSIs) in Lymphocytic leukemia patients with Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) is crucial for optimizing treatment and improving patient outcomes. This retrospective study investigated the prevalence and characteristics of BSIs in these patients diagnosed between 2008 and 2020 at King Abdulaziz University Hospital. Among 1488 patients, 72 cases of BSI were identified, with ALL being the predominant diagnosis (64 cases) and CLL (8 cases). A significant male bias was observed (53 males). Age distribution differed between ALL and CLL, with pediatric patients dominating ALL cases (49) while CLL was primarily diagnosed in the elderly (7 cases). Analysis of causative pathogens revealed a diverse spectrum. Bacterial infections were most prevalent (62 cases), followed by fungal (7 cases) and mixed bacterial-fungal infections (3 cases). Co-infection analysis identified frequent pairings like Staphylococcus with MRSA, E. coli with ESBL, and Klebsiella pneumoniae with Candida parapsilosis. CLL patients displayed a distinct infection pattern, with a higher prevalence of Streptococcus and Candida albicans. We observed differences in the prevalence of specific pathogens based on ALL or CLL diagnosis and remission state. Survival analysis indicated poorer outcomes with increasing age, highlighting the heightened risk associated with advanced age. Our findings emphasize the importance of tailoring infection management strategies based on patient demographics, diagnosis, and remission status for improved outcomes.

31 December 2025 in Genes
Verified
Journal Article
Open access
PDF file
ZDZinab Doha
Zinab Doha
Background/Objectives: Triple-negative breast cancer (TNBC) exhibits high immune infiltration yet remains clinically aggressive. Although immune checkpoint blockade benefits a subset of patients, the molecular programs enabling concurrent immune activation and immune evasion in TNBC are not fully defined. This study aimed to identify TNBC-specific tumor-intrinsic and tumor-extrinsic molecular features that may explain this paradox. Methods: Publicly available single-cell RNA-sequencing data from primary breast tumors were analyzed to characterize subtype-specific transcriptional programs across epithelial and stromal compartments. Tumor-intrinsic findings were independently validated using bulk transcriptomic and clinical data from the METABRIC cohort. Tumor microenvironment remodeling was evaluated using multiplexed tissue imaging of TNBC tumors. Functional analyses were done included Gene Ontology enrichment, Hallmark gene set enrichment analysis, and SERPINB3-centered protein–protein interaction network analysis using STRING. Results: Single-cell analysis identified SERPINB3 as a TNBC-enriched epithelial gene relative to ER+ and HER2+ tumors. This subtype-restricted pattern was validated in the METABRIC cohort and associated with pathways related to epithelial–mesenchymal transition, interferon signaling, and antigen presentation. TNBC tumors also displayed a humoral immune signature characterized by B-cell and plasmablast enrichment, as well as ectopic immunoglobulin gene expression in cancer-associated fibroblasts, endothelial cells, and myeloid populations. Multiplex imaging revealed coordinated associations between immune suppression, stromal activation, and tumor proliferation. Network analysis placed SERPINB3 within interconnected immune-regulatory and stromal signaling modules. Conclusions: Together, these data indicate that TNBC exhibits co-existing immune activation and immune-suppressive features. The identified epithelial and stromal signatures represent candidate biomarkers that may inform future studies of immune regulation and therapeutic stratification in TNBC.

Verified
Journal Article
Open access
PDF file
ZDZinab Doha
Zinab Doha
RARenad R. Alharbi
Renad R. Alharbi
MAMohrah S. Aljohani
Mohrah S. Aljohani
HAHaneen Mohammed Alharbi
Haneen Mohammed Alharbi
HAHakeemah Al-nakhle
Hakeemah Al-nakhle
SAShatha A. Alerwi
Shatha A. Alerwi
Chemotherapy resistance in triple-negative breast cancer (TNBC) remains a critical clinical challenge, with a substantial proportion of patients failing to achieve pathological complete response following neoadjuvant chemotherapy (NAC). Using an integrative single-cell RNA sequencing (scRNA-seq), bulk transcriptomic, and spatial proteomic framework, we aimed to identify the malignant epithelial subset driving this resistance and the intercellular signaling axes through which it reprograms the tumor microenvironment (TME). scRNA-seq analysis of NAC-treated breast tumors revealed a Fatty Acid–EMT co-expressing epithelial subset (FA-EMT) that is selectively enriched in the chemotherapy-resistant residuum. Critically, FA-EMT co-expression—rather than either program individually—most powerfully predicted chemotherapy resistance and reduced overall survival across two independent bulk transcriptomic cohorts comprising 277 TNBC patients (p < 0.001). CellChat ligand–receptor analysis established FA-EMT cells as the dominant TME signaling hub, deploying MDK–NCL and MIF–CD74–CXCR4 axes to simultaneously suppress adaptive and innate anti-tumor immunity via T-cell exhaustion, Treg activation, and the expansion of myeloid-derived suppressor cells. Spatial CyCIF validation in a published paclitaxel-resistant TNBC mouse model (n = 69 cores) confirmed significant Metabolic-EMT enrichment in resistant tumor cores (p = 0.0085) with physical co-localization with immunosuppressive MDSC and Treg populations. These findings establish the FA-EMT subset as a key cellular driver of treatment failure in TNBC and nominate MDK–NCL and MIF–CD74–CXCR4 as mechanistically grounded therapeutic targets with the potential to dismantle the FA-EMT-driven immunosuppressive niche and sensitize chemotherapy-resistant TNBC to cytotoxic treatment.